EnQuest
OTCMKTS:ENQUFEnQuest PLC operates as an oil and gas production and development company, explores, extracts, and produces hydrocarbons in the United Kingdom, North Sea, and Malaysia. It primarily holds interests in the Magnus, Kraken, Golden Eagle, Scolty/Crathes, Greater Kittiwake Area, and Alba; and PM8/Seligi projects. In addition, the company is involved in the construction, ownership, and operation of an oil pipeline; and marketing and trading of crude oil, as well as in leasing activities. The company was incorporated in 2010 and is based in London, the United Kingdom.
Foxtons Group
OTCMKTS:FXTGYFoxtons Group plc, an estate agency, provides services to the residential property market in the United Kingdom. The company operates through three segments: Lettings, Sales, and Financial Services. The Lettings segment engages in letting and management of residential properties. The Sales segment sells residential properties. The Financial Services segment offers mortgages and related products. Foxtons Group plc was founded in 1981 and is headquartered in London, the United Kingdom.
Poxel
OTCMKTS:PXXLFPoxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
The Taiwan Fund
NYSE:TWNThe Taiwan Fund, Inc. is a closed-ended equity mutual fund launched and managed by Nomura Asset Management U.S.A. Inc. It invests in the public equity markets of Taiwan. The fund seeks to invest in stocks of companies operating across diversified sectors. It employs fundamental analysis focusing on such factors as overall growth prospects, competitive position in the respective industry, technology, research, and development, productivity, labor costs, raw material costs and sources, profit margins, return on investment, capital resources, government regulation, and management to create its portfolio. The fund benchmarks the performance of its portfolio against the TAIEX Total Return Index. The Taiwan Fund, Inc. was formed on December 23, 1986 and is domiciled in the United States.